WHO Grade III Glioma Recruiting Phase 2 Trials for Dabrafenib (DB08912)

IndicationStatusPhase
DBCOND0089571 (WHO Grade III Glioma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03919071Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaTreatment